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Background
It is known that tardive dyskinesia (TD) is a major limita-
tion of chronic antipsychotic drug therapy at least with
older (typical) antipsychotics. Atypical antipsychotics
possess a lower extrapyramidal side effects liability. How-
ever, they brought about various side effects such as
weight gain, hyperglycemia, cholesterol level elevation,
and QT interval prolongation. Therefore, it becomes inter-
esting to design compounds that maintain antipsychotic
efficacy and simultaneously could be free of TD risk. In a
previous study we have shown that an indolamine mole-
cule (PBIA, Figure 1) expresses a moderate binding affin-
ity at the dopamine D2 and serotonin 5-HT1A receptors in
in vitro competition binding assays. In the present work,
we tested its p-toluenesulfonyl derivative (TPBIA) for
behavioral effects in rats, related to interactions with cen-
tral dopamine receptors and its antioxidant activity, since
free radical processes are implicated in the pathophysiol-
ogy of a number of CNS disorders, including TD.
Material and Methods
The experimental animals (adult male Fischer-344 rats)
were grouped as: i) Untreated rats: TPBIA was adminis-
tered i.p. in various doses and immediately afterwards the
rats were placed individually in the activity cage and their
motor behaviour was recorded for the next 30 min, ii)
Apomorphine-treated rats: the motor activity was meas-
ured as described above in the rats treated with apomor-
phine (1 mg kg-1, i.p.) 10 min after the administration of
TPBIA. The antioxidant potential of TPBIA was investi-
gated in the model of in vitro non enzymatic lipid
peroxidation.
Results
It was found that: i) In non-pretreated rats, TPBIA reduces
the activity by 39 and 82% respectively, ii) In apomor-
phine pretreated rats, TPBIA (80 µmol/kg) reverses the
hyperactivity and stereotype behaviour induced by apo-
morphine. Also, it was found that TPBIA completely
inhibits the peroxidation of rat liver microsome prepara-
tions at concentrations of 0.5, 0.25 and 0.1 mM.
Discussion
TPBIA might have therapeutic potential in the treatment
of psychosis, due to its dopamine antagonistic activity in
the central nervous system. In addition, its antioxidant
effects is a desirable property, since tardive dyskinesia – a
neuroleptics' side effect – has been attributed, at least in
part, to oxidative stress.
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